Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Boehringer Ingelheim Vetmedica Gmbh patents (2015 archive)


Recent patent applications related to Boehringer Ingelheim Vetmedica Gmbh. Boehringer Ingelheim Vetmedica Gmbh is listed as an Agent/Assignee. Note: Boehringer Ingelheim Vetmedica Gmbh may have other listings under different names/spellings. We're not affiliated with Boehringer Ingelheim Vetmedica Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Boehringer Ingelheim Vetmedica Gmbh-related inventors


12/24/15 / #20150366855

Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (lamas)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (rao), summer pasture associated obstructive pulmonary disease (spaopd), and inflammatory airway disease (iad) in animals, preferably equines such as horses.. ... Boehringer Ingelheim Vetmedica Gmbh

12/10/15 / #20150353610

Novel recombinant outer membrane proteins from brachyspira hyodysenteriae and uses thereof

The present invention relates generally to the field of diarrhoeal diseases caused by intestinal spirochaetes. Specifically, the invention relates to the prevention and/or treatment of infections with b. ... Boehringer Ingelheim Vetmedica Gmbh

12/03/15 / #20150343052

Prevention and treatment of sub-clinical pcvd

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (pcv2) antigen for the prevention and treatment of sub-clinical pcv2 infection in animals, preferably in pigs.. . ... Boehringer Ingelheim Vetmedica Gmbh

11/12/15 / #20150320853

Effective method of treatment of porcine circovirus and lawsonia intracellularis infections

The present invention relates to the use of porcine circovirus type 2 (pcv2) antigen and lawsonia intracellularis (l. Intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against porcine circovirus associated diseases (pcvad) and l. ... Boehringer Ingelheim Vetmedica Gmbh

11/05/15 / #20150313918

Ciclesonide for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (rao), summer pasture associated obstructive pulmonary disease (spaopd), and inflammatory airway disease (iad).. ... Boehringer Ingelheim Vetmedica Gmbh

10/22/15 / #20150297708

Multivalent pcv2 immunogenic compositions and methods of producing such compositions

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant pcv2 orf2 protein, and immunogenic compositions comprising pcv2 orf2 protein. ... Boehringer Ingelheim Vetmedica Gmbh

10/22/15 / #20150297707

Multivalent pcv2 immunogenic compositions and methods of producing such compositions

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant pcv2 orf2 protein, and immunogenic compositions comprising pcv2 orf2 protein. ... Boehringer Ingelheim Vetmedica Gmbh

10/01/15 / #20150274790

Modular antigen transportation molecules and uses therof

The present invention relates to (isolated) recombinant proteins, also referred to as improved mat (imat) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such imat molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. ... Boehringer Ingelheim Vetmedica Gmbh

10/01/15 / #20150273046

Prophylaxis and treatment of prdc

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (pcv2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (prdc) in animals, preferably in pigs.. . ... Boehringer Ingelheim Vetmedica Gmbh

10/01/15 / #20150272977

Treatment of metabolic disorders in equine animals

The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more sglt2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, pituitary pars intermedia dysfunction and/or equine metabolic syndrome in an equine animal.. ... Boehringer Ingelheim Vetmedica Gmbh

09/24/15 / #20150265624

Treatment of epileptic disorders in feline animals

The present invention relates to the use of 1-(4-chlorophenyl)-4-(4-morpholinyl)-2.5-dihydro-1h-imidazol-2-one or a physiologically acceptable salt thereof in a method for treatment and/or prevention of one or more epileptic disorders in a feline animal, preferably a cat.. . ... Boehringer Ingelheim Vetmedica Gmbh

09/03/15 / #20150246113

Porcine parvovirus 5a, methods of use and vaccine

The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5a (ppv5a) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.. ... Boehringer Ingelheim Vetmedica Gmbh

07/23/15 / #20150202282

Pcv2 orf2 virus like particle with foreign amino acid insertion

The present invention comprises methods and compositions related to the production and use of amino acid sequences. In particular, pcv2 orf2 is shown to be useful as a virus-like particle which produces amino acid sequences that retain their immunogenicity or antigenicity when the dna encoding the pcv2 orf2 is inserted into an expression system. ... Boehringer Ingelheim Vetmedica Gmbh

07/09/15 / #20150190498

Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (pcv2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a pcv2 infection. ... Boehringer Ingelheim Vetmedica Gmbh

07/09/15 / #20150190497

Pcv2 immunogenic compositions and methods of producing such compositions

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. ... Boehringer Ingelheim Vetmedica Gmbh

06/25/15 / #20150174233

Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of m. Hyo infection, preferably m. ... Boehringer Ingelheim Vetmedica Gmbh

06/18/15 / #20150164856

Treatment of metabolic disorders in feline animals

The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or syndrome x (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.. . ... Boehringer Ingelheim Vetmedica Gmbh

06/04/15 / #20150150820

Pharmaceutical compositions of pimobendan

The present invention is directed to a composition comprising particles of pimobendan with an integral coating of a carrier matrix which serve to ensure a rapid dissolution of the active substance at each ph condition representing the gastrointestinal tract and therefore a reliable absorption, and a method of pimobendan microencapsulation using the spray congealing technology and incorporating the coated particles into oral formulations, for example into tablets.. . ... Boehringer Ingelheim Vetmedica Gmbh

04/02/15 / #20150093404

Pcv2 orf2 protein variant and virus like particles composed thereof

Vaccination methods to control pcv2 infection with different pcv2 subtypes are disclosed. Specifically, a pcv2 subtype b (pcv2b) orf2 proteins or immunogenic compositions comprising a pcv2b orf2 protein are used in a method for the treatment or prevention of an infection with pcv2 of the same pcv2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with pcv2 of the same pcv2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with pcv2 of the same pcv2b and/or a different subtype. ... Boehringer Ingelheim Vetmedica Gmbh

03/12/15 / #20150072983

Use of dihydroimidazolones for the treatment of dogs

The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1h-imidazol-2-one] (awd 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.. . ... Boehringer Ingelheim Vetmedica Gmbh

03/05/15 / #20150064249

Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof

The invention is directed to a pharmaceutical tablet formulation for the veterinary medical sector containing an instable ace inhibitor or a pharmaceutically acceptable salt thereof as a first pharmaceutically active substance, and pimobendan or a pharmaceutically acceptable salt thereof as a second pharmaceutically active substance, comprising granules which contain carrier core particles coated with at least one layer wherein the first pharmaceutically active substance is present, the granules being embedded in a tablet matrix wherein the second pharmaceutically active substance is present. It is provided a “fixed-dose-combination” which allows to ease the treatment and administration of the medication, improves the medication compliance by reducing the pill burden to the animal holder and enables the better observation of and adherence to the therapy by decreasing the number of tablets to be administered. ... Boehringer Ingelheim Vetmedica Gmbh

02/26/15 / #20150056248

Porcine circovirus type 2 (pcv2) subunit vaccine

Vaccination methods to control pcv2 infection with different pcv2 subtypes are disclosed. Specifically, a pcv2 subtype b (pcv2b) orf2 proteins or immunogenic compositions comprising a pcv2b orf2 protein are used in a method for the treatment or prevention of an infection with pcv2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with pcv2 of a different subtype, or the prevention or treatment of a disease caused by an infection with pcv2 of a different subtype.. ... Boehringer Ingelheim Vetmedica Gmbh

02/26/15 / #20150053207

Inhaler

An inhaler, preferably for insertion into a nostril, in particular a horse's nostril, with an inhalation valve, which has a movable valve element, whereby the valve element is designed in an annular manner and has an outer edge and an inner edge, whereby the valve element is fastened at the outer edge, the inner edge forms the boundary of an indentation of the valve element, and the inhalation valve has a valve body seat that corresponds to the inner edge.. . ... Boehringer Ingelheim Vetmedica Gmbh

02/26/15 / #20150053203

Inhaler

This invention relates to an inhaler with a respiration indicator, whereby the inhaler has a chamber wall forming a chamber and a dispensing device for fluidic connection of the chamber to a bodily opening, preferably a nostril, whereby the respiration indicator has a wall section of the chamber wall or is formed in this way, whereby the wall section is designed to indicate a respiratory activity by deformation and/or movement.. . ... Boehringer Ingelheim Vetmedica Gmbh

02/26/15 / #20150053202

Inhaler

An inhaler, preferably for insertion into a nostril, in particular a horse's nostril, with a pressure generator, which has a tensioning device for the drive, and with a tensioning mechanism for tensioning the tensioning device, whereby the tensioning mechanism has a lever gear for tensioning the tensioning device.. . ... Boehringer Ingelheim Vetmedica Gmbh

02/19/15 / #20150051198

Highly concentrated stable meloxicam solutions for needleless injection

An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.. . ... Boehringer Ingelheim Vetmedica Gmbh

02/05/15 / #20150038441

Kit-in-parts for cleaning and treating ears of companion animals

The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of otitis externa, application and dosage information, cannules, cotton swabs, gauzes and information about the cleaning and maintenance ears of a companion animal.. . ... Boehringer Ingelheim Vetmedica Gmbh

01/22/15 / #20150025082

Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition

The present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising one or more etherified cyclodextrin derivatives; one or more water-soluble preservatives; preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; benzethonium chloride; cetylpyridinium chloride; sodium metabisulfite; sodium acetate; parabenes and salts thereof, preferably methylparabene, ethylparabene, propylparabene, butylparabene, butylparabene sodium; or combinations thereof; and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound, such as pimobendan, in aqueous solution whereby the water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivatives allowing the use in an oral administration form.. ... Boehringer Ingelheim Vetmedica Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Boehringer Ingelheim Vetmedica Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Boehringer Ingelheim Vetmedica Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###